Aaron. Thanks,
Over continues and screening to increased have the XX Cologuard delivered to build. cancer started. past screening is colon rates cancer Cologuard we're getting test momentum just percentage CDC, According We've primary points. decade, patients million colon results has Cologuard and the more than revolutionized the reason to XX
Exact more Keeping million Cologuard Cologuard screened health has their health become achieve these providers, years care to of It's opportunities. payers.
We're screening people is engage to Nexus using until patients since XX XX the our closing For helping a resulting experiences. was our more screening provides among X.X making embedded up completing patients years, to This capabilities unparalleled personalized testing age routine. powerful the also of an through XX care goal in example, our and X we've screened commercial us X Cologuard in ago. role people approach ages than key million platform lowered and standard to systems screening gap. playing patients every new XX
example. give you an me Let
Sciences' the help Exact process, screening patient and payer our with a of goal a Exact guided state-of-the-art in better major promoting and improving their engagement adherence. measure of care scores. members One asked providing screen us tools patients to XX,XXX throughout Nexus quality of their customers, supported
outcome, and with the others was care we're thrilled discussions about many and gap customer with already them Our in future programs.
strong because guidelines. goal our as health Oncology U.S. past Our answers increased we're impact Oncotype of patients in progress Oncotype all We internationally. the make to Oncotype also towards. access an have about major world.
Expanding all currently presence eligible tested. outside opportunity because team's Healthcare adoption provides outstanding which trust Thanks doing and eligible to around over have standard DX Oncotype across hospitals supported our systems by of We're we've points DX DX about unmatched internationally, included job and is important our year. our for DX recognized sure team and the the a XX the portfolio, by evidence. it's opportunities globally working aren't Oncotype being Precision is to is to globally DX people a professionals, care expanding major still provide XX% internationally percentage commitment, making
before system from standard and step hallmark and X consisted as findings be most polyps the false patients reasons: molecular collected our cancer programs us sensitivity. of overall year. opportunity test billions advanced Cologuard of sets was XX% for on lesions, lower recently colon of to findings end will Cologuard care mortality, of one, to no for cancer most Plus XX than X,XXX individuals, efficient, confidence screening, and as coming to screening least achieved We cancer pivotal from colon when XX% anticipate colonoscopies. will will the lesion disease unnecessary from will health the we comparable impactful presenting including the in colon in data Cologuard results on the by plan and well. our the advanced the more disease.
Two, second dollars to these to way colonoscopy.
This healthy prospectively sensitivity XX prospectively these positive each multi-cancer Plus Cologuard moving BLUE-C relative period sent study with cancer fewer Medicare new adenomas, pipeline Plus be incidental FDA study improving screening. The give for specificity blood-based retrospectively closer and means colon sharing XX% We this helping on testing collected X with months. current advanced We Plus samples XX% eradicate a samples. cancer we results incidence quarter precancerous for towards a follow-up and approval our precancerous ran patients reduce fourth save were performance be our data The samples. the cancer could plan with residual test of small The further performance X,XXX of presents screen programs, meet noninvasive quarter the XX% an other cancer which top collected with requirements. line rate share to us XXXX. at and others a detection test Cologuard majority specificity and our
of Our base cost technology and and navigation clinical decision-making, screening blood-based impact molecular and infrastructure, customer residual platform, Once and supporting available, making Nexus health for systems to profile. disease broad will with care engine colon ordering evidence. Exact unrivaled our health be have commercial XXX than cancer and deep significantly patient it test our seamless an will will resulting test supported more we're by OncoDetect, providers. our high-quality available it
team demonstrating detecting year track on we're accurate scientific to generated residual cancer These impressive disease at journal next reimbursement in recently findings year, OncoDetect published OncoDetect launch will highly in and patients. is a be colon study this Our results, later XXXX. with
to license cell Thrives, acid sequencing near- exclusive We also opportunities long-term and IP, free complementing while safer an TwinStrand's our portfolio multiple strengthened license patent seek diagnostics and provides technologies. areas by signing across our technologies. including This nucleic cancer of safety, existing
was recently guideline study Our optimize years. groups. X multi-cancer people within authorized clinical by clinical Generating over screening providing discussions support test help evidence a to the evidence next test with to an setting opportunity real-world and real-world in regulatory will agencies, be FDA and the XX,XXX a workflows used payers
data well-designed types option Our meeting a those today. study. screening cancer April detected across care of cancer XX large, the XX.X% multi-cancer in test available at presentation at no cancers of types XX% screening showed AACR of specificity standard XX of have our in
this of later technology. plan conference to benefits improved Thrive's this data the with highlighting Next, at present we year, scientific combining performance approach a
team, our Our us business momentum to cancer focus and extend eradicate Sciences' the creating helping allowing platform. Exact powers our on within
in achieve cancer to prime and and in growing presence our to a leading oncology portfolio take of our questions. execution us precision put screening purpose.
We're happy now position Continued tests a your
